{
  "id": 1967963,
  "title": "BioStem Technologies at Micro-Cap Virtual Conference: shift to hospitals",
  "url": "https://urgent.news/2026/08/19/biostem-technologies-at-micro-cap-virtual-conference-shift-to",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T15:45:31.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/biostem-technologies-at-microcap-virtual-conference-shift-to-hospitals-93CH-4867882"
  },
  "original_language": "en",
  "account": "On Wednesday, August 19, 2026, BioStem Technologies (BSEM) unveiled a new business strategy at the Micro-Cap Virtual Conference. The company has shifted its focus from wound care to a more diversified regenerative medicine platform, targeting hospitals and surgery. CEO Jason Matuszewski explained that BioStem was once wound-centric, reliant on CMS wound reimbursement and physician offices. The company is now surgical-centric, with a broader commercial payers, CMS, hospital, and office presence, supported by a direct sales force, independent agents, and distributors.\n\nMatuszewski highlighted the most significant change: a shift in reimbursement mix. Previously, 100% of revenue was product-based reimbursement, dictated by CMS pricing. Now, 87% of revenue comes from surgical procedural-based reimbursement under DRG, with the remaining 13% still tied to product-based reimbursement. This change is the key to de-risking the company's business model.\n\nThe company's addressable market is approximately $26 billion, with about $15.3 billion in wound care and $11 billion in surgical opportunities. Although the company currently has limited penetration in the surgical market, there is significant room for growth. Lastly, BioStem reported Q2 2026 revenue of $7.9 million, up 29% from $6.1 million in Q1. Hospital revenue increased to $6.7 million from $5.7 million, while physician office revenue rose to $1.1 million from $800,000. However, year-over-year revenue fell from $11.0 million in Q2 2025 due to a CMS pricing reset in the BioRetain wound-care business.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Innovative Eyewear at Sidoti Micro-Cap Investor Conference: growth push",
        "url": "https://urgent.news/2026/08/19/innovative-eyewear-at-sidoti-micro-cap-investor-conference-growth-push",
        "published": "2026-08-19T15:44:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}